Showing 1 - 20 results of 8,678 for search '(( its ((greater decrease) OR (a decrease)) ) OR ( a ((larger decrease) OR (marked decrease)) ))', query time: 0.73s Refine Results
  1. 1

    Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer by Ben J. Haines (22458462)

    Published 2025
    “…Papaverine is typically used as a vasorelaxant due to its ability to inhibit phosphodiesterase 10A (PDE10A), which can lead to unwanted side effects when used clinically as a radiosensitizer. …”
  2. 2

    Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer by Ben J. Haines (22458462)

    Published 2025
    “…Papaverine is typically used as a vasorelaxant due to its ability to inhibit phosphodiesterase 10A (PDE10A), which can lead to unwanted side effects when used clinically as a radiosensitizer. …”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Average days to heal a wound in 2022 and 2023. by Heba Tallah Mohammed (2822432)

    Published 2025
    “…Larger PIs (>4 cm²) showed greater reductions, with time to improvement decreasing by 35.5 days (34.7%, p < 0.001). …”
  8. 8

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    “…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
  9. 9

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    “…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
  10. 10

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    “…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
  11. 11
  12. 12

    Image 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf by Kai Sun (140584)

    Published 2025
    “…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
  13. 13

    Table 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

    Published 2025
    “…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
  14. 14

    Table 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

    Published 2025
    “…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
  15. 15

    Image 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf by Kai Sun (140584)

    Published 2025
    “…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
  16. 16

    Data Sheet 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

    Published 2025
    “…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
  17. 17

    Data Sheet 1_Persistent lymphopenia after kidney transplantation: increased mortality and decreased homeostatic mechanisms.docx by Yun Liang (383275)

    Published 2025
    “…The major risk factors for lymphopenia at 3 years were: receiving alemtuzumab or rATG for induction or the treatment of rejection, increasing recipient age, pretransplant dialysis, a low lymphocyte count pretransplant, and having a prior kidney transplant. …”
  18. 18
  19. 19
  20. 20